Ability to drive [1], NSAID ---> SmPC of [1] of eMC
Dizziness, drowsiness, fatigue and visual disturbances may occur
ACE inhibitors, NSAID
Concomitant use of NSAIDs and ACE inhibitors may increase the risk of renal failure and hyperkalemia.
ACE inhibitors, NSAID ---> SmPC of [Bupivacaine/meloxicam] of EMA
Co-administration of an NSAID with ACE inhibitors or angiotensin-II antagonists may result in deterioration of renal function, including possible acute renal failure
Acebutolol, NSAID
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Aceclofenac [1], NSAID ---> SmPC of [1] of eMC
Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects, including GI bleeding
Acemetacine, NSAID
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Acenocoumarol [1], NSAID ---> SmPC of [1] of eMC
Drugs altering haemostasis may potentiate the anticoagulant activity and increase the risk of haemorrhage. The use concomitant is not recommended
Acetylcholine, NSAID
There have been reports that acetylcholine and carbachol have been ineffective when used in patients treated with topical non-steroidal anti-inflammatory agents.
Acetylsalicylic acid [1], NSAID ---> SmPC of [1] of eMC
Increased risk of ulcerations and gastrointestinal bleeding due to synergistic effects.
Afamelanotide [1], NSAID ---> SmPC of [1] of EMA
Patients taking substances which reduce coagulation, acetylsalicylic acid and non-steroidal anti-inflammatory drug (NSAIDs) may experience increased bruising or bleeding at the site of implantation.
AIIRA, NSAID ---> SmPC of [irbesartan] of EMA
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Alcohol, NSAID ---> SmPC of [dexibuprofen] of eMC
Enhancement of the adverse effects of the NSAID, especially those of the gastrointestinal tract
Alendronate, NSAID ---> SmPC of [alendronic acid/colecalciferol] of EMA
Since non-Steroidal Anti-Inflammatory Drug (NSAID) use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.
Alendronate/colecalciferol [1], NSAID ---> SmPC of [1] of EMA
Since non Steroidal Anti-Inflammatory Drug (NSAID) use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.
Alendronic acid, NSAID ---> SmPC of [alendronic acid/colecalciferol] of EMA
Since Non-Steroidal Anti-Inflammatory Drug (NSAID) use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.
Alendronic acid/colecalciferol [1], NSAID ---> SmPC of [1] of EMA
Since Non-Steroidal Anti-Inflammatory Drug (NSAID) use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.
Algeldrate/magnesium hydroxide, NSAID
The co-administration of aluminium-containing antacids with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 2 hours
Aliskiren [1], NSAID ---> SmPC of [1] of EMA
NSAIDs may reduce the anti-hypertensive effect of aliskiren. Concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium levels may lead to increases in serum potassium.
Aliskiren/amlodipine [1], NSAID ---> SmPC of [1] of EMA
As with other medicinal products acting on the renin-angiotensin-aldosterone system, NSAIDs may reduce the anti-hypertensive effect of aliskiren. The combination of aliskiren with an NSAID requires caution
Aliskiren/amlodipine/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of EMA
As with other agents acting on the renin-angiotensin system, NSAIDs may reduce the anti-hypertensive effect of aliskiren. NSAIDs may also weaken the diuretic and antihypertensive activity of hydrochlorothiazide.
Aliskiren/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of EMA
NSAIDs may reduce the anti-hypertensive effect of aliskiren. NSAIDs may weaken the diuretic and antihypertensive activity of hydrochlorothiazide.
Almasilate, NSAID
There are studies which describe an absorption reduction of the active principle co-administered with almasilate
Alprostadil, NSAID
NSAID decreases the endogen prostaglandin synthesis and decreases its effect
Aluminium hydroxide, NSAID
The co-administration of aluminium-containing antacids with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 2 hours
Aluminium oxide/magnesium hydroxide, NSAID
The co-administration of aluminium-containing antacids with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 2 hours
Amiloride, NSAID ---> SmPC of [amiloride/hydrochlorothiazide] of eMC
Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia
Amiloride/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of eMC
NSAIDs may reduce the effect of antihypertensive drugs, including the diuretic, natriuretic and antihypertensive effects of diuretics. Co-administration of NSAIDs and potassium-sparing agents may cause hyperkalemia, particularly in elderly patients.
Aminoglycoside antibiotics, NSAID ---> SmPC of [dexibuprofen] of eMC
Co-administration of aminoglycoside antibiotics with NSAIDs may increase the risk of nephrotoxicity on account of reduced synthesis of prostaglandins in the kidney. During combination treatment renal function must be closely monitored
Amlodipine/valsartan [1], NSAID ---> SmPC of [1] of EMA
Concomitant use of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Amlodipine/valsartan/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of EMA
NSAIDS can attenuate the antihypertensive effect of both AIIRA and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use may lead to worsening of renal function and an increase in serum potassium.
Angiotonin antagonist, NSAID
Attenuation of the antihypertensive effect. Increased risk of worsening of renal function and increase in serum potassium. The concomitant use should be done with caution
Antacids, NSAID
Antacid decreases the absorption of NSAID. Separate administration by at least 2 hours
Antihypertensives, NSAID ---> SmPC of [parecoxib] of EMA
NSAIDs may reduce the effect antihypertensive medicinal products.
Apixaban [1], NSAID ---> SmPC of [1] of EMA
Apixaban should be used with caution when co-administered with NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk.
Asparaginase [1], NSAID ---> SmPC of [1] of EMA
Concomitant use of glucocorticoids and/ or anticoagulants with asparaginase may increase the risk of a change in coagulation parameters (see section 4.4). This can promote tendency to bleeding (anticoagulants) or thrombosis (glucocorticoids).
Atenolol [1], NSAID ---> SmPC of [1] of eMC
Non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. indometacin) may reduce the hypotensive effect of beta-blockers.
Atenolol/chlortalidone [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of prostaglandin synthetase-inhibiting drugs may decrease the hypotensive effects of beta-blockers.
Atenolol/nifedipine [1], NSAID ---> SmPC of [1] of eMC
Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the hypotensive effect of beta-blockers.
Azapropazone, NSAID
The co-administration is contraindicated in patients with porphyria
Azilsartan medoxomil [1], NSAID ---> SmPC of [1] of EMA
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may attenuate the antihypertensive effect, lead to an increased risk of worsening of renal function and an increase in serum potassium.
Azilsartan [1], NSAID ---> SmPC of [1] of eMC
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Baclofen, NSAID
NSAIDs possibly reduce excretion of baclofen (increased risk of toxicity).
Bemiparin, NSAID
The concomitant administration of bemiparin and NSAIDs is not advisable. Increased risk of bleeding.
Benazepril, NSAID
Concomitant use of NSAIDs and ACE inhibitors may increase the risk of renal failure and hyperkalemia.
Bendroflumethiazide, NSAID
Non-steroidal anti-inflammatory agents may blunt the diuretic and antihypertensive effects of thiazide diuretics. Diuretics may increase the risk of nephrotoxicity of NSAIDs.
Betablockers, NSAID ---> SmPC of [propranolol] of EMA
Non-steroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-blocking agents.
Betaxolol, NSAID
NSAIDs (especially indometacin) may reduce the antihypertensive effects of beta-blockers possibly by inhibiting renal prostaglandin synthesis and/or causing sodium and fluid retention.
Bile-acid sequestrants, NSAID
Bile acid sequestrant may decrease the absorption of NSAID
Biphosphonates, NSAID ---> SmPC of [ibandronic acid] of EMA
Since Acetylsalicylic acid, Nonsteroidal Anti-Inflammatory medicinal products (NSAIDs) and bisphosphonates are associated with gastrointestinal irritation, caution should be taken during concomitant administration
Bisoprolol [1], NSAID ---> SmPC of [1] of eMC
NSAIDs may reduce the hypotensive effect of bisoprolol.
Breast-feeding [1], NSAID ---> SmPC of [1] of eMC
NSAIDs should, if possible, be avoided when breastfeeding.
Bumetanide [1], NSAID ---> SmPC of [1] of eMC
Certain non-steroidal anti-inflammatory drugs have been shown to antagonise the action of diuretics.
Bupivacaine, NSAID
Increased bleeding tendency
Calcineurin inhibitors, NSAID
Nephrotoxicity of calcineurin inhibitor may be enhanced by NSAIDs via renal prostaglandin-mediated effects.
Candesartan cilexetil [1], NSAID ---> SmPC of [1] of eMC
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Candesartan [1], NSAID ---> SmPC of [1] of eMC
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Captopril [1], NSAID ---> SmPC of [1] of eMC
It has been described NSAIDs and ACE inhibitors exert an additive effect on the increase in serum potassium whereas renal function may decrease. Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE inhibitor.
Carbachol [1], NSAID ---> SmPC of [1] of eMC
Carbachol may be ineffective when is used with topic NSAIDs
Carbaldrate, NSAID
The aluminium salt decreases the absorption of the co-administered active principle. Separate administration by at least 2 hours
Cardiac glycosides, NSAID
NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycoside levels when co-administered with cardiac glycosides.
Carteolol, NSAID
Reduction of the antihypertensive effect
Carvedilol [1], NSAID ---> SmPC of [1] of eMC
The antihypertensive effect of carvedilol is decreased due to water and sodium retention.
Celiprolol [1], NSAID ---> SmPC of [1] of eMC
Drugs inhibiting prostaglandin synthetase may decrease the hypotensive effects of beta-adrenoceptor blocking drugs.
Certolizumab pegol [1], NSAID ---> SmPC of [1] of EMA
Concomitant treatment with methotrexate, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics showed no effect on the pharmacokinetics of certolizumab pegol based on a population pharmacokinetics analysis.
Chlorpropamide, NSAID
The NSAID can increase the hypoglycaemic effect of sulfonylureas by displacement from plasma protein binding sites. Caution is recommended
Chlortalidone, NSAID
The co-administration may decrease the diuretic and antihypertensive effect of diuretic
Cilazapril [1], NSAID ---> SmPC of [1] of eMC
When ACE inhibitors are administered simultaneously with NSAIDs attenuation of the antihypertensive effect may occur. Concomitant use may also lead to an increased risk of worsening of renal function, and an increase in serum potassium
Citalopram [1], NSAID ---> SmPC of [1] of eMC
Caution is warranted for patients who are being treated simultaneously with anticoagulants, medicinal products that affect platelet function, or other medicines that can increase the risk of haemorrhage
Clodronate [1], NSAID ---> SmPC of [1] of eMC
Patients receiving NSAIDs in addition to sodium clodronate have developed renal dysfunction.
Clodronic acid [1], NSAID ---> SmPC of [1] of eMC
Patients receiving NSAIDs in addition to sodium clodronate have developed renal dysfunction.
Clofarabine [1], NSAID ---> SmPC of [1] of EMA
The concomitant use of medicinal products eliminated by tubular secretion should be avoided
Clonidine, NSAID
The co-administration of clonidine and drugs that retain water or sodium may decrease the hypotensive effect of clonidine
Clopamide, NSAID
Decreased diuretic and antihypertensive effect
Clopidogrel [1], NSAID ---> SmPC of [1] of EMA
NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution
Clopidogrel/acetylsalicylic acid [1], NSAID ---> SmPC of [1] of EMA
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. Consequently, the concomitant use of NSAIDs including Cox-2 inhibitors is not recommended
Cloprednol, NSAID
Increased risk of gastrointestinal haemorrhage
Colchicine, NSAID
The co-administration may decrease the effect of colchicine and/or increase its toxicity
Corticosteroids, NSAID ---> SmPC of [methylprednisolone] of eMC
There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs.
Coumarin anticoagulants, NSAID ---> SmPC of [naproxen/esomeprazole] of eMC
NSAIDs may enhance the effects of oral anti-coagulants (e.g. warfarin, dicoumarol)
Coxibs, NSAID
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Cyclosporine [1], NSAID ---> SmPC of [1] of eMC
Care should be taken when using ciclosporin together with other active substances that exhibit nephrotoxic synergy
Dabigatran etexilate [1], NSAID ---> SmPC of [1] of EMA
With chronic use NSAIDs increased the risk of bleeding. Close observation for signs of bleeding is recommended
Dabigatran [1], NSAID ---> SmPC of [1] of EMA
With chronic use NSAIDs increased the risk of bleeding. Close observation for signs of bleeding is recommended
Dalteparin [1], NSAID ---> SmPC of [1] of eMC
NSAIDs reduce production of vasodilatatory prostaglandins, and thereby renal blood flow and the renal excretion. Caution is recommended
Dapoxetine [1], NSAID ---> SmPC of [1] of eMC
There have been reports of bleeding abnormalities with SSRIs. Caution is advised in patients taking dapoxetine, particularly in concomitant use with medicinal products known to affect platelet function
Daptomycin [1], NSAID ---> SmPC of [1] of EMA
The co-administration with medicinal products that reduce renal filtration may decrease the plasma levels of daptomycin and additive renal effects
Deferasirox [1], NSAID ---> SmPC of [1] of EMA
The concomitant administration of deferasirox with substances that have known ulcerogenic potential, such as NSAIDs (including acetylsalicylic acid at high dosage), may increase the risk of gastrointestinal toxicity
Defibrotide [1], NSAID ---> SmPC of [1] of EMA
Medicinal products that affect platelet aggregation should be administered with care, under close medical supervision
Deflazacort, NSAID
Increased risk of gastrointestinal haemorrhage
Delapril, NSAID
The co-administration of ACE inhibitors with long-term NSAIDs may decrease the antihypertensive effect, increase the risk of renal failure and cause hypercaliemia.
Desirudin [1], NSAID ---> SmPC of [1] of EMA
Desirudin should be used with caution in conjunction with medicinal products which affect platelet function
Desmopressin [1], NSAID ---> SmPC of [1] of eMC
NSAIDs may induce water retention and/or hyponatraemia.
Dexibuprofen [1], NSAID ---> SmPC of [1] of eMC
The concomitant use with other NSAIDs should be avoided, since simultaneous administration of different NSAIDs can increase the risk of gastrointestinal ulceration and haemorrhage.
Dexketoprofen [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Dibotermin alfa [1], NSAID ---> SmPC of [1] of EMA
Mild or moderate adverse events related to wound healing. An interaction between NSAIDs and dibotermin alfa cannot be excluded.
Diclofenac [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Digoxin, NSAID ---> SmPC of [dexibuprofen] of eMC
NSAID may exacerbate cardiac failure, reduce the glomerular filtration rate and increase plasma levels of the cardiac glycoside
Dimethyl fumarate [1], NSAID ---> SmPC of [1] of EMA
Concurrent therapy of dimethyl fumarate with nephrotoxic medicinal may increase the potential of renal adverse reactions (e.g. proteinuria)
Dinoprostone, NSAID
NSAID decreases the endogen prostaglandin synthesis and decreases its effect
Diuretics, NSAID ---> SmPC of [parecoxib] of EMA
NSAIDs may reduce the effect of diuretics.
Doxazosin, NSAID
The co-administration may weaken the hypotensive effect
Drotrecogin alfa [1], NSAID ---> SmPC of [1] of EMA
Caution should be employed when using drotrecogin alfa with other drugs that affect haemostasis
Edoxaban [1], NSAID ---> SmPC of [1] of EMA
In clinical studies, co-administration of NSAIDs resulted in increased clinically relevant bleeding. Chronic use of NSAIDs with edoxaban is not recommended.
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil [1], NSAID ---> SmPC of [1] of EMA
Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil fumarate and with risk factors for renal dysfunction.
Emtricitabine/rilpivirine/tenofovir disoproxil [1], NSAID ---> SmPC of [1] of EMA
If Eviplera is co-administered with an NSAID, renal function should be monitored adequately.
Emtricitabine/tenofovir disoproxil [1], NSAID ---> SmPC of [1] of EMA
Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in HIV-1 infected patients treated with tenofovir disoproxil fumarate and with risk factors for renal dysfunction.
Enalapril [1], NSAID ---> SmPC of [1] of eMC
Antihypertensive effect of ACE inhibitors may be attenuated by NSAIDs including selective COX-2 inhibitors. The co-administration of NSAIDs (including COX-2 inhibitors) and ACE inhibitors exert an additive effect on the increase in serum potassium
Enalapril/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of eMC
The antihypertensive effect of ACE inhibitors or diuretics may be attenuated by NSAIDs. The co-administration of NSAIDs and ACE inhibitors exert an additive effect on the increase in serum potassium
Enoxaparin sodium [1], NSAID ---> SmPC of [1] of EMA
It is recommended that agents which affect haemostasis should be discontinued prior to enoxaparin therapy unless their use is essential.
Enoxaparin [1], NSAID ---> SmPC of [1] of eMC
The co-administration may enhance the pharmacologic effect and increase the bleeding risk. A close clinical and laboratory monitoring is recommended
Eplerenone [1], NSAID ---> SmPC of [1] of eMC
Treatment of eplerenone with NSAIDs may lead to acute renal failure by acting directly on glomerular filtration, especially in at-risk patients
Epoprostenol [1], NSAID ---> SmPC of [1] of eMC
When NSAIDS or other drugs affecting platelets aggregation are used concomitantly, there is the potential for epoprostenol to increase the risk of bleeding.
Eprosartan [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of renal function worsening, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Erlotinib [1], NSAID ---> SmPC of [1] of EMA
Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based chemotherapy are at increased risk of gastrointestinal perforation
Ertugliflozin/metformin [1], NSAID ---> SmPC of [1] of EMA
Some medicinal products can adversely affect renal function, which may increase the risk of lactic acidosis
Escitalopram [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of escitalopram with non-steroidal anti-inflammatory drugs (NSAIDs) may increase bleeding-tendency
Esmolol [1], NSAID ---> SmPC of [1] of eMC
NSAIDs may decrease the hypotensive effects of beta-blockers.
Etoricoxib [1], NSAID ---> SmPC of [1] of eMC
The co-administration of etoricoxib with other NSAIDs is not recommended
Febuxostat [1], NSAID ---> SmPC of [1] of EMA
Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat.
Felodipine/ramipril [1], NSAID ---> SmPC of [1] of eMC
The co-administration of ACE inhibitors with NSAIDs may decrease the ramipril effect, increase the risk of renal failure and cause hypercaliemia.
Fertility, NSAID
NSAIDs may impair female fertility and is not recommended in women attempting to conceive
Fludrocortisone, NSAID
Corticosteroids may increase the incidence and/or severity of GI bleeding and ulceration associated with NSAIDS.
Fluocortolone, NSAID
Increased risk of gastrointestinal haemorrhage and ulceration.
Fluoxetine [1], NSAID ---> SmPC of [1] of eMC
Caution is advised in patients taking SSRIs, particularly in concomitant use with oral anticoagulants, drugs known to affect platelet function or other drugs that may increase risk of bleeding as well as in patients with a history of bleeding disorders.
Flurbiprofen [1], NSAID ---> SmPC of [1] of eMC
Avoid concomitant use of two or more NSAIDs, including Cox-2 inhibitors, as this may increase the risk of adverse effects
Fluvoxamine [1], NSAID ---> SmPC of [1] of eMC
Caution is advised in patients taking SSRIs particularly in elderly patients and in patients who concomitantly use drugs known to affect platelet function or drugs that increase risk of bleeding
Fondaparinux [1], NSAID ---> SmPC of [1] of EMA
Other antiplatelet medicinal products and NSAIDs should be used with caution. If co-administration is essential, close monitoring is necessary.
Foods, NSAID
Take with food to reduce the gastrointestinal irritation
Forasartan, NSAID
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Fosinopril [1], NSAID ---> SmPC of [1] of eMC
NSAIDs may interfere with the antihypertensive effect. As with any ACE inhibitor, in some patients with compromised renal function the co-administration of fosinopril and NSAIDs may result in a further deterioration of renal function.
Fossil tree, NSAID ---> SmPC of [ibuprofen] of eMC
Ginkgo biloba with NSAID may increase the risk of bleeding
Furosemide [1], NSAID ---> SmPC of [1] of eMC
NSAID may reduce the diuretic effects of furosemide.
Gestagens, NSAID
Special care should be taken when progestogens are administered with other drugs which also cause fluid retention, such as NSAIDs and vasodilators.
Glibenclamide [1], NSAID ---> SmPC of [1] of EMA
Highly protein-bound medicinal products, which may also potentiate the hypoglycaemic action of glibenclamide due to glibenclamide displacement from plasma proteins
Gliclazide [1], NSAID ---> SmPC of [1] of eMC
Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur when nonsteroidal anti-inflammatory agents are taken
Glipizide, NSAID
NSAIDs can increase the hypoglycaemic effect of sulfonylureas by displacement from plasma protein binding sites.
Gliquidone [1], NSAID ---> SmPC of [1] of eMC
NSAIDs can increase the hypoglycaemic effect of sulfonylureas by displacement from plasma protein binding sites.
Glucocorticoids, NSAID ---> SmPC of [methylprednisolone] of eMC
There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs.
Glycerol trinitrate, NSAID
Concurrent administration may potentiate the blood pressure lowering effects of nitroglycerin.
Glycerol trinitrate, NSAID
Concurrent administration may potentiate the blood pressure lowering effects of nitroglycerin.
Heparin calcium, NSAID ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Heparin, NSAID ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Hydantoins, NSAID
The co-administration may increase the toxic effects of hydantoin and is not recommended
Hydralazine [1], NSAID ---> SmPC of [1] of eMC
Concurrent treatment of hydralazine may decrease the effects
Hydrochlorothiazide, NSAID
NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics
Hydrocortisone, NSAID
Increased risk of gastrointestinal haemorrhages
Hyperkalemia, NSAID ---> SmPC of [dexibuprofen] of eMC
As with other NSAIDs, concomitant treatment with drugs increasing potassium plasma levels, may be associated with increased serum potassium levels and may increase the risk of renal failure
Ibandronic acid [1], NSAID ---> SmPC of [1] of EMA
Since Acetylsalicylic acid, Nonsteroidal Anti-Inflammatory medicinal products (NSAIDs) and bisphosphonates are associated with gastrointestinal irritation, caution should be taken during concomitant administration
Ibuprofen [1], NSAID ---> SmPC of [1] of EMA
The concomitant use of more than one NSAID should be avoided because of the increased risk of adverse reactions.
Iloprost [1], NSAID ---> SmPC of [1] of EMA
Since iloprost inhibits platelet function its use with anticoagulants or other inhibitors of platelet aggregation may increase the risk of bleeding. A careful monitoring of the patients is recommended.
Imidapril [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Indapamide [1], NSAID ---> SmPC of [1] of eMC
Possible reduction in the antihypertensive effect of indapamide. Risk of acute renal failure in dehydrated patients (decreased glomerular filtration).
Indometacin, NSAID
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Intrauterine device, NSAID
NSAID decreases the efficacy of intrauterine devices
Irbesartan [1], NSAID ---> SmPC of [1] of EMA
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
Irbesartan/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of EMA
NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists.
Kebuzone, NSAID
Kebuzone should not be co-administered with other NSAIDs
Ketoprofen [1], NSAID ---> SmPC of [1] of eMC
Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects, particularly gastrointestinal ulceration and bleeding.
Ketorolac [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Labetalol, NSAID
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Leflunomide [1], NSAID ---> SmPC of [1] of EMA
If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, these may be continued after starting leflunomide.
Levofloxacin [1], NSAID ---> SmPC of [1] of EMA
A pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other substances which lower the seizure threshold
Linaclotide [1], NSAID ---> SmPC of [1] of EMA
Concomitant treatment with proton pump inhibitors, laxatives or NSAIDs may increase the risk of diarrhoea.
Linagliptin/metformin [1], NSAID ---> SmPC of [1] of EMA
Special caution should be exercised in situations where renal function may become impaired. In these cases, it is recommended to check renal function before initiating treatment with metformin.
Lisinopril [1], NSAID ---> SmPC of [1] of eMC
Chronic administration of NSAIDs may reduce the antihypertensive effect of an ACE inhibitor. NSAIDs and ACE inhibitors exert an additive effect on the increase in serum potassium and may result in a deterioration of renal function.
Lithium carbonate [1], NSAID ---> SmPC of [1] of eMC
Serum lithium levels may be increased. Monitor serum lithium concentrations more frequently if NSAID therapy is initiated or discontinued.
Lithium, NSAID
The inhibition of the renal excretion of lithium may increase plasma concentrations and toxicity of lithium. Caution is recommended
Lithium, NSAID ---> SmPC of [Bupivacaine/meloxicam] of EMA
NSAIDs have been reported to increase blood lithium levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended.
Loop diuretics, NSAID
The co-administration may decrease the diuretic effect and increase the risk of renal failure secondary to a reduction in renal blood flow.
Lornoxicam, NSAID
The co-administration may increase the risk of bleeding
Losartan [1], NSAID ---> SmPC of [1] of eMC
When AIIRAs are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Concomitant use of AIIRA and NSAIDs may lead to an increased risk of worsening of renal function, and an increase in serum potassium
Losartan/hydrochlorothiazide [1], NSAID ---> SmPC of [1] of eMC
When AIIRAs are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect, increased risk of worsening of renal function, and an increase in serum potassium may occur
Lumiracoxib, NSAID
Lumiracoxib may be used with low dose of acetylsalicylic acid. Concomitant use of lumiracoxib with high doses of acetylsalicylic acid, other NSAIDs or COX-2 inhibitors should be avoided
Medroxyprogesterone, NSAID [2] ---> SmPC of [2] of eMC
Special care should be taken when progestogens are administered with other drugs which also cause fluid retention, such as NSAIDs and vasodilators.
Mefruside, NSAID
Reduced diuretic and antihypertensive effect of diuretic. Diuretic can increase the risk of nephrotoxicity of the NSAID
Meglumine and sodium ioxitalamate, NSAID
The co-administration with other medicinal products with nephrotoxic potential may decrease the renal function and cause a permanent damage
Melagatran, NSAID
The co-administration may increase the bleeding risk
Meloxicam, NSAID
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Mesalazine [1], NSAID ---> SmPC of [1] of eMC
Caution is recommended for the concomitant use of mesalazine with known nephrotoxic agents, as these may increase the risk of renal adverse reactions.
Metformin/saxagliptin/dapagliflozin [1], NSAID ---> SmPC of [1] of EMA
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis. When starting or using such product in combination with metformin, close monitoring of renal function is necessary.
Methotrexate [1], NSAID ---> SmPC of [1] of EMA
In animal experiments non-steroidal anti-inflammatory drugs (NSAIDs) including salicylic acid caused reduction of tubular methotrexate secretion and consequently increased its toxic effects.
Methyldopa [1], NSAID ---> SmPC of [1] of eMC
NSAIDs antagonise the hypotensive effect.
Methylprednisolone, NSAID
Increased risk of gastrointestinal haemorrhage and ulceration.
Metildigoxin, NSAID
Increased plasma levels of metildigoxin
Metolazone, NSAID
The co-administration may weaken the hypotensive effect
Mifamurtide [1], NSAID ---> SmPC of [1] of EMA
It has been demonstrated in vitro that high-dose NSAIDs (cyclooxygenase inhibitors) can block the macrophage activating effect of liposomal mifamurtide. Therefore, the use of high-dose NSAIDs is contraindicated
Mifepristone, NSAID ---> SmPC of [ibuprofen] of eMC
NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effects of mifepristone.
Misoprostol [1], NSAID ---> SmPC of [1] of eMC
Concomitant administration of NSAIDs and misoprostol in rare cases can cause a transaminase increase and peripheral oedema.
Moexipril, NSAID
The co-administration of ACE inhibitors with long-term NSAIDs may decrease the antihypertensive effect, increase the risk of renal failure and cause hypercaliemia.
Nabumetone [1], NSAID ---> SmPC of [1] of eMC
The use of nabumetone with concomitant NSAIDs, including cyclooxygenase-2 selective inhibitors should be avoided
Nadolol [1], NSAID ---> SmPC of [1] of eMC
The antihypertensive effects of beta blockers may be reduced during concurrent administration of indometacin and possibly other NSAIDs.
Nadroparin, NSAID
The co-administration may increase the nadroparin effect
Naproxen [1], NSAID ---> SmPC of [1] of eMC
Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects
Naproxen/esomeprazole [1], NSAID ---> SmPC of [1] of eMC
Concomitant use of two or more NSAIDs should be avoided as this may increase the risk of adverse effects, especially gastrointestinal ulcers and bleeding.
Nateglinide [1], NSAID ---> SmPC of [1] of EMA
Non-steroidal anti-inflammatory agents may enhance the hypoglycaemic effect of nateglinide
Nebivolol [1], NSAID ---> SmPC of [1] of eMC
Non-steroidal anti-inflammatory drugs (NSAID) are thought to have no effect on the blood pressure lowering effect of nebivolol.
Nephrotoxic substances, NSAID
The co-administration may increase the risk of renal adverse reactions
Nimesulide, NSAID
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
Nitroglycerine, NSAID
Concurrent administration may potentiate the blood pressure lowering effects of nitroglycerin.
Norfloxacin, NSAID
The NSAID can increase the risk of convulsions associated with quinolone antibiotic.
NSAID [1], sulfinpyrazone ---> SmPC of [1] of eMC
Non-steroidal antirheumatic drugs may exert a synergistic effect on the blood coagulation system and thus increase the risk of haemorrhage.
NSAID, NSAID
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, ofloxacin [2] ---> SmPC of [2] of eMC
There may be a further lowering of the cerebral seizure threshold when quinolones are given concurrently with other drugs which lower the seizure threshold
NSAID, olmesartan ---> SmPC of [olmesartan medoxomil] of eMC
NSAIDs (including ASA at doses >3g/day and also COX-2 inhibitors) and AIIRAs may act synergistically by decreasing glomerular filtration (risk of acute renal failure). Additionally, concomitant treatment can reduce the antihypertensive effect of AIIRAs
NSAID, olmesartan medoxomil [2] ---> SmPC of [2] of eMC
NSAIDs (including ASA at doses >3g/day and also COX-2 inhibitors) and AIIRAs may act synergistically by decreasing glomerular filtration (risk of acute renal failure). Additionally, concomitant treatment can reduce the antihypertensive effect of AIIRAs
NSAID, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC
When AIIRA are coadministered with NSAIDs, attenuation of the antihypertensive effect may occur. Moreover, this combination may increase the risk of worsening of renal function and may lead to an increase in serum potassium
NSAID, oral anticoagulants ---> SmPC of [flurbiprofen] of eMC
NSAIDs may enhance the effects of anticoagulants such as warfarin
NSAID, oral antidiabetics
Hypoglycaemic and hyperglycaemic effects.
NSAID, oxaprozin
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, oxprenolol [2] ---> SmPC of [2] of eMC
Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the hypotensive effect of beta-blockade.
NSAID, parecoxib ---> SmPC of [meloxicam] of eMC
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, parnaparin
Increased bleeding risk (the NSAID inhibits the platelet function and damages the gastrointestinal mucosa)
NSAID, paroxetine [2] ---> SmPC of [2] of eMC
Concomitant use of paroxetine and NSAIDs/acetylsalicylic acid can lead to an increased haemorrhagic risk.
NSAID, peanut protein [2] ---> SmPC of [2] of EMA
The potential for allergic reactions to occur if taking non- steroidal anti-inflammatory medicines whilst on PALFORZIA treatment should be considered.
NSAID, pegaspargase [2] ---> SmPC of [2] of EMA
The use of Oncaspar can lead to fluctuating coagulation factors. This can promote the tendency to bleeding and/or thrombosis. Caution is therefore needed when anticoagulants are given concomitantly.
NSAID, pemetrexed [2] ---> SmPC of [2] of EMA
Caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
NSAID, penicillamine
Concomitant use of penicillamine with NSAID may increase the risk of renal damage
NSAID, pentazocine
Seizures may occur with nonsteroidal anti-inflamatory drugs
NSAID, pentosan polysulfate sodium [2] ---> SmPC of [2] of EMA
Patients who are concomitantly treated should be evaluated for any haemorrhagic event in order to adapt the dose if needed
NSAID, pentoxifylline
The co-administration may increase the risk of bleeding. Increase clinical monitoring and check bleeding time more often
NSAID, perindopril [2] ---> SmPC of [2] of eMC
When ACE-inhibitors are administered simultaneously with NSAIDS attenuation of the antihypertensive effect, an increased risk of worsening of renal function, including possible acute renal failure and an increase in serum potassium may occur
NSAID, phenindione
The co-administration is not recommended since it may increase the intensity of bleedings
NSAID, phenprocoumon
Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of drugs that cause gastrointestinal mucosal injury
NSAID, phenylbutazone
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, phenytoin [2] ---> SmPC of [2] of eMC
Non-steroidal antirheumatics may increase phenytoin serum levels
NSAID, pindolol
The NSAID can reduce the anti-hypertensive effect of beta-blocker
NSAID, pindolol/clopamide
Concomitant use of pindolol/clopamide and NSAIDS may decrease the diuretic and hypotensive effect of pindolol/clopamide
NSAID, pioglitazone [2] ---> SmPC of [2] of EMA
Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors.
NSAID, piretanide
NSAIDs may weaken the antihypertensive and diuretic effect of piretanide
NSAID, piroxicam [2] ---> SmPC of [2] of eMC
The use of piroxicam together with other NSAIDs, including other piroxicam formulations, must be avoided, since data are inadequate to show that such combinations produce greater improvement than that achieved with piroxicam alone
NSAID, platelet aggregation inhibitors
NSAIDs may enhance the effects of thrombocyte aggregation inhibitors
NSAID, potassium
Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia
NSAID, potassium canrenoate
The co-administration of NSAIDs with potassium canreonate may cause hyperpotassemia and decrease the diuretic effect of potassium canreonate
NSAID, potassium chloride [2] ---> SmPC of [2] of eMC
Combined treatment with NSAIDs increases the risk of hyperkalaemia
NSAID, potassium sodium hydrogen citrate
The NSAID decreases the renal elimination of potassium
NSAID, potassium-sparing diuretics ---> SmPC of [amiloride/hydrochlorothiazide] of eMC
Concomitant administration of NSAIDs and potassium-sparing agents may cause hyperkalemia, particularly in elderly patients.
NSAID, prasugrel [2] ---> SmPC of [2] of EMA
Because of the potential for increased risk of bleeding, chronic NSAIDs (including COX-2 inhibitors) and Efient should be co-administered with caution
NSAID, prazosin
The co-administration may decrease the hypotensive effect
NSAID, prednisolone
The ulcerogenic effect of NSAID may increase
NSAID, prednisone [2] ---> SmPC of [2] of eMC
The risk of gastrointestinal haemorrhages is increased.
NSAID, primidone
Primidone, enzymatic inductor, may accelerate the metabolism of NSAID and decrease its plasma levels and effect
NSAID, probenecide
The co-administration may delay the elimination of NSAID and increase its plasma levels, effects and adverse reactions
NSAID, procaine
Enhancement of an existent haemorrhagic diathesis
NSAID, proglumetacine
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, propranolol [2] ---> SmPC of [2] of EMA
Non-steroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-blocking agents.
NSAID, prostaglandins
NSAID decreases the endogen prostaglandin synthesis and decreases its effect
NSAID, quinapril [2] ---> SmPC of [2] of eMC
The antihypertensive effect of ACE inhibitors may be attenuated by NSAIDs. Co-administration of NSAIDs with ACE inhibitors may result in deterioration of renal function, including possible acute renal failure.
NSAID, quinolones ---> SmPC of [flurbiprofen] of eMC
Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.
NSAID, quinolones ---> SmPC of [levofloxacin] of EMA
A pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other substances which lower the seizure threshold
NSAID, ramipril [2] ---> SmPC of [2] of eMC
Reduction of the antihypertensive effect of ramipril is to be anticipated. Furthermore, concomitant treatment of ACE inhibitors and NSAIDs may lead to an increased risk of worsening of renal function and to an increase in kalaemia.
NSAID, repaglinide [2] ---> SmPC of [2] of EMA
NSAIDs may enhance and/or prolong the hypoglycaemic effect of repaglinide.
NSAID, reviparin
Caution is recommended when coadministering reviparin with NSAIDs due to increased bleeding risk
NSAID, ripisartan
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
NSAID, rivaroxaban [2] ---> SmPC of [2] of EMA
Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products
NSAID, sacubitril/valsartan [2] ---> SmPC of [2] of EMA
In elderly patients, volume-depleted patients (including those on diuretic therapy), or patients with compromised renal function, concomitant use of Entresto and NSAIDs may lead to an increased risk of worsening of renal function.
NSAID, salicylates
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, saprisartan
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
NSAID, saralasin
Attenuation of the antihypertensive effect. Increased risk of worsening of renal function and increase in serum potassium. The concomitant use should be done with caution
NSAID, sertraline [2] ---> SmPC of [2] of EMA
The risk of bleeding may be increased when medicines acting on platelet function or other medicines that might increase bleeding risk are concomitantly administered with SSRIs
NSAID, sirolimus ---> SmPC of [dexibuprofen] of eMC
Concomitant administration of sirolimus with NSAIDs may increase the risk of nephrotoxicity on account of reduced synthesis of prostaglandins in the kidney. During combination treatment renal function must be closely monitored
NSAID, sitagliptin/metformin [2] ---> SmPC of [2] of EMA
There is increased risk of lactic acidosis in acute alcohol intoxication due to the metformin active substance of Efficib. Consumption of alcohol and medicinal products containing alcohol should be avoided
NSAID, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
NSAID, sotalol
The inhibition of prostaglandin synthesis may decrease the antihypertensive effect of betablocker
NSAID, spirapril
NSAID may decrease the anti-hypertensive effect.
NSAID, spironolactone [2] ---> SmPC of [2] of eMC
There may be an increased risk of nephrotoxicity and hyperkalaemia when NSAIDs are used with spironolactone.
NSAID, SSRI ---> SmPC of [sertraline] of EMA
The risk of bleeding may be increased when medicines acting on platelet function or other medicines that might increase bleeding risk are concomitantly administered with SSRIs
NSAID, streptokinase [2] ---> SmPC of [2] of eMC
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
NSAID, streptokinase/streptodornase
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
NSAID, strong diuretic agents
The co-administration may increase the nephrotoxicity risk. Concomitant use should be avoided
NSAID, sulfonylureas
NSAIDs can increase the hypoglycaemic effect of sulfonylureas by displacement from plasma protein binding sites.
NSAID, sulindac
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, sulphonamides
The co-administration may increase the toxic effects of sulfonamide and is not recommended
NSAID, sulprostone
The co-administration may decrease desirable effects of sulprostone. The combination has to be avoided
NSAID, tacrolimus [2] ---> SmPC of [2] of EMA
Concurrent use of tacrolimus with medicinal products known to have nephrotoxic or neurotoxic effects may increase these effects
NSAID, tafamidis [2] ---> SmPC of [2] of EMA
Tafamidis inhibits the uptake transporters OAT1 and OAT3 (organic anion transporters) and may cause drug-drug interactions at clinically relevant concentrations with substrates of these transporters
NSAID, tasosartan
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
NSAID, telmisartan [2] ---> SmPC of [2] of EMA
The combination of AIIRAs and AIIRAs (selective COX-2 inhibitors, ASA (> 3 g/day) and non-selective NSAIDs) may decrease the antihypertensive effect, increase the renal failure risk and cause hypercaliemia
NSAID, telmisartan/amlodipine [2] ---> SmPC of [2] of EMA
NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.
NSAID, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and the antihypertensive effects of angiotensin II receptor antagonists.
NSAID, tenofovir disoproxil
Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil fumarate and with risk factors for renal dysfunction.
NSAID, tenofovir [2] ---> SmPC of [2] of EMA
Concomitant administration of tenofovir disoproxil fumarate and NSAIDs may increase the risk of renal failure.
NSAID, tenoxicam [2] ---> SmPC of [2] of eMC
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, terazosine [2] ---> SmPC of [2] of eMC
Non-steroidal antirheumatics may reduce the antihypertensive effect of terazosin.
NSAID, tetracosactide
Increased risk of gastrointestinal haemorrhage and ulceration. Caution is recommended
NSAID, thiazides
NSAIDs may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics
NSAID, thrombolytics
Increased risk of bleeding due to inhibition of the platelet function.
NSAID, tiaprofenic acid
Concomitant use of several NSAIDs should be avoided due to an increased risk of adverse effects, particularly upper gastrointestinal disorders.
NSAID, ticagrelor [2] ---> SmPC of [2] of EMA
Ticagrelor should be used with caution with medicinal products that may increase the risk of bleeding
NSAID, ticlopidine [2] ---> SmPC of [2] of eMC
It is considered unsafe to take NSAIDs in combination with platelet aggregation inhibitors due to increased risk of bleeding. If coadministration is unavoidable, patient should be closely monitored.
NSAID, tinzaparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of tinzaparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
NSAID, tocilizumab [2] ---> SmPC of [2] of EMA
Population pharmacokinetic analyses did not detect any effect of MTX, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids on tocilizumab clearance.
NSAID, tolperisone
Tolperisone may increase the effect of NSAID
NSAID, torasemid [2] ---> SmPC of [2] of eMC
Non-steroidal anti-inflammatory drugs may reduce the diuretic and hypotensive effect of torasemide.
NSAID, trandolapril [2] ---> SmPC of [2] of eMC
As with antihypertensives, NSAIDs may reduce the antihypertensive effects of trandolapril. An additive effect on serum potassium increase has been described when NSAIDs and ACE inhibitors have been used concomitantly, while renal function may be reduced.
NSAID, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
The administration of NSAIDs may reduce the antihypertensive effect of an ACE inhibitor. It has been described that NSAIDs and ACE inhibitors exert an additive effect on the increase in serum potassium, whereas renal function may decrease.
NSAID, treprostinil
Treprostinil may inhibit platelet function. Concomitant administration of treprostinil with platelet aggregation inhibitors, including NSAIDs, nitric oxide donors or anticoagulants may increase the risk of bleeding.
NSAID, triamcinolone acetonide
Corticosteroids may increase the incidence and/or severity of GI bleeding and ulceration associated with NSAIDs.
NSAID, triamcinolone [2] ---> SmPC of [2] of eMC
Corticosteroids may increase the incidence and/or severity of GI bleeding and ulceration associated with NSAIDs.
NSAID, triamterene
It is advisable to monitor blood urea and serum potassium levels periodically in patients receiving triamterene concomitant with NSAIDs.
NSAID, triamterene/hydrochlorothiazide
Salicylates and NSAIDs may decrease the antihypertensive and diuretic effect of triamterene/hydrochlorothiazide
NSAID, triflusal
The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid, impairs the serum protein binding of NSAID and increases the plasma levels of NSAIDs.
NSAID, trimethoprim
The co-administration may cause hypercaliemia.
NSAID, urokinase [2] ---> SmPC of [2] of eMC
Due to increased risk of haemorrhage, concomitant use of urokinase and active substances that affect platelet function should be avoided
NSAID, valdecoxib
Increased risk of gastrointestinal adverse effects (ulcers between other complications)
NSAID, valsartan [2] ---> SmPC of [2] of eMC
When AIIRAs are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, the concomitant use may lead to an increased risk of worsening of renal function and an increase in serum potassium.
NSAID, venlafaxine
Possible prolongation of bleeding time. Caution is recommended
NSAID, vorapaxar [2] ---> SmPC of [2] of EMA
The use of certain concomitant medicinal products (e.g., chronic nonsteroidal anti-inflammatory drugs (NSAIDS)) may increase the risk of bleeding in patients taking vorapaxar.
NSAID, vortioxetine [2] ---> SmPC of [2] of EMA
Caution should be exercised when vortioxetine is combined with oral anticoagulants or antiplatelet medicinal products due to a potential increased risk of bleeding
NSAID, warfarin [2] ---> SmPC of [2] of eMC
NSAIDs potentiate the effect of warfarin
NSAID, ximelagatran
The co-administration may increase the bleeding risk
NSAID, xipamide
Possible decrease of the antihypertensive and diuretic effect of xipamide
NSAID, zidovudine ---> SmPC of [flurbiprofen] of eMC
Increased risk of haematological toxicity when NSAIDs are given with zidovudine
NSAID, zofenopril
The administration of NSAIDS may reduce the antihypertensive effect of an ACE inhibitor. Furthermore, it has been described that NSAIDS and ACE inhibitors exert an additive effect on the increase in serum potassium whereas renal function may decrease.